IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION

IN RE NATIONAL PRESCRIPTION OPIATE LITIGATION

MDL No. 2804

This document relates to:

Case No. 17-md-2804

Track One Cases

Hon. Dan Aaron Polster

NOTICE OF SERVICE OF TEVA AND ACTAVIS GENERIC DEFENDANTS' MOTION FOR SUMMARY JUDGMENT

Pursuant to the Directions Regarding Filing of Briefs Under Seal, ECF No. 1719, Defendants¹ hereby provide notice that on June 28, 2019, they served unredacted copies of the following documents on all Parties, the Court, and the Special Masters:

- Teva and Actavis Generic Defendants' Motion for Summary Judgment;
- Memorandum in Support of Teva and Actavis Generic Defendants' Motion for Summary Judgment;
- Declaration of Steven A. Reed, along with all corresponding Exhibits;
- [Proposed] Order Granting Teva and Actavis Generic Defendants' Motion for Summary Judgment; and
- Summary Sheet for Teva and Actavis Generic Defendants' Motion for Summary Judgment (also attached hereto as Exhibit A).

Cephalon and Teva USA are referred to as the "Teva Defendants." Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc., Warner Chilcott Company, LLC, Actavis South Atlantic LLC, Actavis Elizabeth LLC, Actavis Mid Atlantic LLC, Actavis Totowa LLC, Actavis Kadian LLC, Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc.-Salt Lake City, and Actavis Laboratories FL, Inc., f/k/a Watson Laboratories, Inc.-Florida are collectively referred to as the "Actavis Generic Defendants." In addition, Teva Pharmaceutical Industries Ltd., is an Israeli corporation that is not subject to and contests personal jurisdiction for the reasons explained in its pending motion to dismiss for lack of personal jurisdiction; it is specially appearing to join this motion as a result of the Court's summary judgment deadline, and, thus, does not waive and expressly preserves its pending personal jurisdiction challenges.

Dated: June 28, 2019 Respectfully submitted,

By: /s/ Steven A. Reed
Steven A. Reed
Eric W. Sitarchuk
Rebecca J. Hillyer
MORGAN, LEWIS & BOCKIUS LLP
1701 Market St.
Philadelphia, PA 19103-2921
Tel: (215) 963-5603
steven.reed@morganlewis.com

eric.sitarchuk@morganlewis.com rebecca.hillyer@morganlewis.com

Nancy L. Patterson MORGAN, LEWIS & BOCKIUS LLP 1000 Louisiana Street, Suite 4000 Houston, TX 77002-5005 Tel: (713) 890-5195 nancy.patterson@morganlewis.com

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131-2339 Tel: (305) 415-3000 brian.ercole@morganlewis.com

Attorneys for Cephalon, Inc., Teva
Pharmaceuticals USA, Inc., Watson Laboratories,
Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a
Watson Pharma, Inc., Warner Chilcott Company,
LLC, Actavis South Atlantic LLC, Actavis
Elizabeth LLC, Actavis Mid Atlantic LLC, Actavis
Totowa LLC, Actavis Kadian LLC, Actavis
Laboratories UT, Inc. f/k/a Watson Laboratories,
Inc.-Salt Lake City, and Actavis Laboratories FL,
Inc., f/k/a Watson Laboratories, Inc.-Florida, and
appearing specially for Teva Pharmaceutical
Industries Ltd.

CERTIFICATE OF SERVICE

I, Steven A. Reed, hereby certify that the foregoing document was served via the Court's ECF system to all counsel of record.

/s/ Steven A. Reed Steven A. Reed